Creekmur Asset Management LLC Acquires 4,260 Shares of Agilent Technologies, Inc. (NYSE:A)

Creekmur Asset Management LLC increased its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 32,769.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,273 shares of the medical research company's stock after buying an additional 4,260 shares during the quarter. Creekmur Asset Management LLC's holdings in Agilent Technologies were worth $500,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in A. Jennison Associates LLC boosted its holdings in shares of Agilent Technologies by 17.6% in the 1st quarter. Jennison Associates LLC now owns 439,112 shares of the medical research company's stock valued at $51,367,000 after purchasing an additional 65,731 shares in the last quarter. Retirement Planning Co of New England Inc. bought a new position in shares of Agilent Technologies in the 1st quarter valued at $324,000. Bailard Inc. lifted its stake in shares of Agilent Technologies by 6.6% in the 1st quarter. Bailard Inc. now owns 2,631 shares of the medical research company's stock valued at $308,000 after acquiring an additional 163 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Agilent Technologies by 35.0% in the 1st quarter. Larson Financial Group LLC now owns 5,991 shares of the medical research company's stock valued at $701,000 after acquiring an additional 1,554 shares during the last quarter. Finally, Wealthfront Advisers LLC lifted its stake in shares of Agilent Technologies by 1.4% in the 1st quarter. Wealthfront Advisers LLC now owns 17,364 shares of the medical research company's stock valued at $2,031,000 after acquiring an additional 233 shares during the last quarter.

Agilent Technologies Stock Performance

Shares of NYSE:A traded down $2.39 during mid-day trading on Friday, reaching $113.97. The company had a trading volume of 1,521,841 shares, compared to its average volume of 1,861,582. The company has a current ratio of 2.09, a quick ratio of 1.60 and a debt-to-equity ratio of 0.55. The firm has a market cap of $32.38 billion, a price-to-earnings ratio of 28.14, a PEG ratio of 3.53 and a beta of 1.23. The company's 50-day moving average price is $116.04 and its 200-day moving average price is $122.16. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.63 billion. During the same quarter in the previous year, the firm posted $1.22 EPS. The business's revenue for the quarter was up 6.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 23rd. Investors of record on Tuesday, July 1st will be paid a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.87%. Agilent Technologies's dividend payout ratio is presently 24.44%.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Leerink Partners raised their target price on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Friday, May 30th. Barclays lifted their price objective on Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research report on Tuesday, June 24th. Wall Street Zen upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, June 28th. Evercore ISI lifted their target price on Agilent Technologies from $125.00 to $130.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Finally, Jefferies Financial Group reduced their price objective on shares of Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $139.77.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares of the company's stock, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.